大脑叶酸运输缺陷在2个病例中与不可吸收的肌性
Marian Y Girgis1, Eman Mahfouz1, Alshaimaa Abdellatif1
1Department of Pediatrics, Neurometabolic Unit, Faculty of Medicine, Cairo University, Cairo, Egypt.
Journal of epilepsy research
|July 9, 2024
概括
由FOLR1基因突变引起的大脑叶酸运输缺陷,损害叶酸运输,导致神经问题. 用叶酸早期治疗对于患病儿童的更好的结果至关重要.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 儿科 儿科 儿科
背景情况:
- 大脑叶酸运输缺陷源于叶酸受体1 (FOLR1) 基因的突变.
- 这种遗传缺陷扰乱了血脑屏障的叶酸运输,导致脑脊液 (CSF) 中的5-甲基四基叶酸水平较低.
研究的目的:
- 报告两例儿童脑叶酸运输缺陷的病例.
- 要突出临床表现,诊断方法和治疗结果.
主要方法:
- 两名被诊断患有脑叶酸运输缺陷的儿童的临床病例报告.
- 神经成像 (MRI和CT扫描) 来评估大脑结构.
- 整体外基因组测序以识别FOLR1基因中的致病变体.
主要成果:
- 两名女性患者呈现出发育迟缓,衰退,发作,震,小头症,低血压和性衰竭.
- 遗传分析显示,这两位患者的FOLR1基因都存在同卵性致病变体.
- 用叶酸治疗减少了发作的频率,但由于启动延迟,治疗并没有完全有效.
结论:
- 在患有全球发育迟缓,难治性,缺氧,小脑缩和大脑化的儿童中,应怀疑大脑叶酸运输缺陷.
- 早期诊断和迅速启动叶酸治疗对于改善患者的治疗结果至关重要.
- 延迟治疗可能导致对叶酸补充剂的部分反应.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
316
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
316
Antiepileptic Drugs: GABAergic Pathway Potentiators
380
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
380
Antiepileptic Drugs: Potassium Channel Activators
165
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
165
Inborn Errors of Metabolism
153
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
153
Arteries of the Lower Limbs
186
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
186
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
284
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
284


